Tim Robertson
Papers
1
Total Citations
13
H-Index
1
About
Tim Robertson is a leading translational researcher in urologic oncology, whose work bridges the gap between cancer immunotherapy and focal therapies for prostate cancer. His primary research areas center on the immunomodulatory effects of localised cancer treatments, particularly irreversible electroporation (IRE), and how these interventions can prime systemic anti-tumour immune responses. Robertson’s major contribution is the landmark IRE-IMMUNO study, which prospectively compared the systemic immune effects of IRE against robot-assisted radical prostatectomy. This work demonstrated that IRE not only downregulates local immune suppression but also induces robust, systemic T-cell activation, offering a compelling rationale for combining focal ablation with immunotherapy. With 13 citations since its 2024 publication, the study has rapidly shaped clinical thinking about the immune consequences of treatment selection. Robertson’s research is notable for its direct translational impact, providing mechanistic insights that could redefine standard-of-care sequencing in intermediate-risk prostate cancer. His findings challenge the conventional surgical paradigm, positioning IRE as both a therapeutic and immunopriming strategy. For students and researchers, Robertson’s work exemplifies how rigorous clinical immunology can uncover new dimensions of existing technologies, opening avenues for combination therapies that harness the patient’s own immune system against residual or metastatic disease.
Research Focus
Key Achievements
Top Papers
- 1